JP2003516394A5 - - Google Patents

Download PDF

Info

Publication number
JP2003516394A5
JP2003516394A5 JP2001543523A JP2001543523A JP2003516394A5 JP 2003516394 A5 JP2003516394 A5 JP 2003516394A5 JP 2001543523 A JP2001543523 A JP 2001543523A JP 2001543523 A JP2001543523 A JP 2001543523A JP 2003516394 A5 JP2003516394 A5 JP 2003516394A5
Authority
JP
Japan
Prior art keywords
crystalline form
celecoxib
phase purity
crystalline
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001543523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003516394A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/032760 external-priority patent/WO2001042222A1/en
Publication of JP2003516394A publication Critical patent/JP2003516394A/ja
Publication of JP2003516394A5 publication Critical patent/JP2003516394A5/ja
Withdrawn legal-status Critical Current

Links

JP2001543523A 1999-12-08 2000-12-01 セレコキシブの多型結晶形態 Withdrawn JP2003516394A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16985699P 1999-12-08 1999-12-08
US60/169,856 1999-12-08
PCT/US2000/032760 WO2001042222A1 (en) 1999-12-08 2000-12-01 Polymorphic crystalline forms of celecoxib

Publications (2)

Publication Number Publication Date
JP2003516394A JP2003516394A (ja) 2003-05-13
JP2003516394A5 true JP2003516394A5 (cg-RX-API-DMAC7.html) 2008-01-24

Family

ID=46125623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001543523A Withdrawn JP2003516394A (ja) 1999-12-08 2000-12-01 セレコキシブの多型結晶形態

Country Status (27)

Country Link
US (1) US7476744B2 (cg-RX-API-DMAC7.html)
EP (2) EP1528058A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003516394A (cg-RX-API-DMAC7.html)
AT (1) ATE288897T1 (cg-RX-API-DMAC7.html)
AU (1) AU750978B2 (cg-RX-API-DMAC7.html)
BR (1) BR0008088A (cg-RX-API-DMAC7.html)
CA (1) CA2362675A1 (cg-RX-API-DMAC7.html)
CY (1) CY1106307T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20013210A3 (cg-RX-API-DMAC7.html)
DE (1) DE60018040T2 (cg-RX-API-DMAC7.html)
DK (1) DK1150960T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ3140A1 (cg-RX-API-DMAC7.html)
EA (1) EA003464B1 (cg-RX-API-DMAC7.html)
EE (1) EE200100419A (cg-RX-API-DMAC7.html)
GE (1) GEP20043180B (cg-RX-API-DMAC7.html)
HR (1) HRP20010589A2 (cg-RX-API-DMAC7.html)
IL (1) IL144799A (cg-RX-API-DMAC7.html)
IS (1) IS6042A (cg-RX-API-DMAC7.html)
MX (1) MXPA01008161A (cg-RX-API-DMAC7.html)
NO (1) NO321062B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ514059A (cg-RX-API-DMAC7.html)
PL (1) PL349224A1 (cg-RX-API-DMAC7.html)
SI (1) SI1150960T1 (cg-RX-API-DMAC7.html)
SK (1) SK11522001A3 (cg-RX-API-DMAC7.html)
UA (1) UA74539C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001042222A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200207445B (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001872A3 (tr) 2000-06-26 2002-01-21 Fako Ilaclari A.S 4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine iliskin yöntem.
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2004078163A2 (en) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
IL163846A0 (en) 2002-03-01 2005-12-18 Univ South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
AU2002251330A1 (en) * 2002-04-25 2003-11-10 Generics (Uk) Limited Celecoxib forms
AU2002251329A1 (en) * 2002-04-25 2003-11-10 Generics (Uk) Limited Novel crystalline forms of celecoxib and other compounds
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
ATE550022T1 (de) * 2003-02-28 2012-04-15 Mcneil Ppc Inc Pharmazeutische mischkristalle von celecoxib- nicotinamid
WO2005014546A1 (en) * 2003-08-08 2005-02-17 Hetero Drugs Limited Novel crystalline forms of celecoxib
WO2006051340A1 (en) * 2004-07-22 2006-05-18 Pliva - Istrazivanje I Razvoj D.O.O. Novel form of celecoxib
CA2589167A1 (en) 2004-11-23 2006-06-01 Pliva Hrvatska D.O.O. Extended release pharmaceutical composition of celecoxib
CA2595675A1 (en) * 2005-01-31 2006-08-03 Pharmacia & Upjohn Company Llc Form iv crystalline celecoxib
PE20070548A1 (es) * 2005-09-19 2007-07-12 Emisphere Tech Inc Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
PT2404919E (pt) 2005-11-08 2013-10-22 Vertex Pharma Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp
EP2164840A2 (en) 2007-05-09 2010-03-24 Vertex Pharmaceuticals Incorporated Modulators of cftr
HUE049642T2 (hu) 2007-12-07 2020-09-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái
CA2989620C (en) 2007-12-07 2022-05-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
CA2716109C (en) 2008-02-28 2016-07-19 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
CN102089051A (zh) * 2008-07-11 2011-06-08 巴斯夫欧洲公司 作为形态学改变剂的两亲性蛋白质
WO2010037066A2 (en) * 2008-09-29 2010-04-01 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2011055233A2 (en) 2009-11-03 2011-05-12 Actavis Group Ptc Ehf Improved process for preparing celecoxib polymorph
US20110213159A1 (en) 2010-03-01 2011-09-01 Vamsee Krishna Muppidi Process for preparation of celecoxib crystalline form
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN103130684A (zh) * 2013-03-22 2013-06-05 南开大学 美索巴莫磷酸二钾盐的多晶型及其制备方法
CN103193677A (zh) * 2013-03-22 2013-07-10 南开大学 美索巴莫磷酸二钠盐的多晶型及其制备方法
CA2930199C (en) 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
AU2015377253A1 (en) * 2015-01-13 2017-08-31 Autotelic Llc Method for individualized drug therapy
JP6499948B2 (ja) * 2015-09-09 2019-04-10 株式会社トクヤマ セレコキシブii型結晶の製造方法
WO2019031902A2 (ko) 2017-08-11 2019-02-14 (주)아모레퍼시픽 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물
KR102518632B1 (ko) 2018-04-18 2023-04-06 (주)아모레퍼시픽 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물
CN113005176A (zh) * 2019-12-20 2021-06-22 深圳市帝迈生物技术有限公司 稳定剂、凝血酶原时间检测试剂及其制备方法、试剂盒
CN119656108B (zh) * 2025-02-21 2025-05-30 墨格微流科技(汕头)有限公司 一种米诺地尔纳米晶混悬液及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
WO1993025190A1 (en) 1992-06-10 1993-12-23 Eastman Kodak Company Surface modified nsaid nanoparticles
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
CA2277954A1 (en) * 1993-11-30 1995-06-08 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5981576A (en) 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
EP0863134A1 (en) 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
AU3762699A (en) 1998-04-27 1999-11-16 Pacific Northwest Cancer Foundation (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
JP2002534509A (ja) * 1999-01-14 2002-10-15 メルク フロスト カナダ アンド カンパニー 4−[(5−置換または未置換フェニル)−3−置換−1h−ピラゾール−1−イル]ベンゼンスルホンアミド類の合成
WO2000066562A1 (en) * 1999-05-03 2000-11-09 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
JP2004500358A (ja) * 1999-12-08 2004-01-08 ファルマシア コーポレイション バイオアベイラビリティーが増加した固体状態のセレコキシブ
TR200001872A3 (tr) * 2000-06-26 2002-01-21 Fako Ilaclari A.S 4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine iliskin yöntem.

Similar Documents

Publication Publication Date Title
CA2537092A1 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP2007532560A5 (cg-RX-API-DMAC7.html)
CA2514169A1 (en) Process for obtaining 17.alpha.-acetoxy-11.beta.(4-n,n-dimethylaminophenyl-19-norpregna-4,9-diene-3,20-dione
CA2632585A1 (en) Novel modifications to 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonyl-aminobenzene and processes for preparing said compound
CA2410234C (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
CA2056067A1 (en) A physical form of n-¬4-¬5-(cyclopentyloxcarbony)-amino-1-methylindol-3-yl-methyi|-3-methoxybenzoy1|-2-methyibezenesulphonanide, processes for its preparation and compositions containing it
AU2001264804A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
JP2003514859A5 (cg-RX-API-DMAC7.html)
ZA200207675B (en) Novel crystal form of pyrrolidylthiocarbapenem derivative.
JP2016510767A5 (cg-RX-API-DMAC7.html)
EP1903041A3 (en) Polymorphic and other crystalline forms of cis-FTC
JP6091881B2 (ja) BaTi2O5系複合酸化物の製造方法
JP2024515770A5 (cg-RX-API-DMAC7.html)
JP2004530660A5 (cg-RX-API-DMAC7.html)
BS et al. Nanocrystalline icosahedral phase formation in melt spun Ti-Zr-Ni alloys
RU2003106718A (ru) Способ получения мелкодисперсного порошка титана
JP2002316865A5 (cg-RX-API-DMAC7.html)
JP2010540440A5 (cg-RX-API-DMAC7.html)
JP2002020525A5 (cg-RX-API-DMAC7.html)
JP2001011580A5 (cg-RX-API-DMAC7.html)
JP2005501857A5 (cg-RX-API-DMAC7.html)
JPH04244067A (ja) ヘキサヒドロピリダジン−1,2−ジカルボキシ誘導体の製造法
JP2002506064A5 (cg-RX-API-DMAC7.html)
JPS542912A (en) Sintered hard alloy
Liu et al. Amorphization tendency of Ti sub 34 Zr sub 11 Cu sub 47 Ni sub 8 and Ti sub 37 Zr sub 17 Cu sub 42 Ni sub 4 during mechanical alloying